High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study

Affiliations

• ¹ Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA.
• ² Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
• ³ Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD, USA.
• ⁴ Xavier University of Louisiana, New Orleans, LA, USA.
• ⁵ Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore, MD, USA.
• ⁶ Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
• ⁷ Food and Drug Administration, Silver Spring, MD, USA.
• ⁸ Biostatistics Research Branch, NIAID, NIH, Bethesda, MD, USA.
• ⁹ Gilead Sciences Inc., Foster City, CA, USA.
• ¹⁰ Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. [email protected].
• ¹¹ Division of Infectious Diseases, Institute of Human Virology, University of Maryland, Baltimore, MD, USA. [email protected].
• ¹² Division of Clinical Care and Research, Institute of Human Virology, N222, University of Maryland School of Medicine, 725 West Lombard St, Room S222, Baltimore, MD, 21201, USA. [email protected].
• ¹³ Division of Hepatology, St. Josephs Hospital and Medical Center, Creighton University Medical School, Phoenix, AZ, USA.